Sci-Tech Innovation 200 ETF Penghua(588240) actively traded, pharmaceutical sector active against the trend

The pharmaceutical sector is active despite the broader market moving against it. On the news front, in 2025, China’s innovative drug BD overseas licensing hit a record high; after entering 2026, the momentum has continued. As of March 27, the total licensing transaction amount for overseas authorizations has already exceeded $60 billion. In addition, the global partnership value of domestically developed innovative drugs continues to be realized. Furthermore, Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has approved its GLP-1 oral medication for market launch.

Institutional analysts noted that today’s market performance was weaker due to the impact of “negative developments from overseas + cautious positioning ahead of the holiday.” Trading activity has been subdued, and the indices have been moving within a narrow range. Looking ahead, market sentiment remains cautious. On one hand, the market is still paying close attention to the situation in the Middle East; on the other hand, during the dense earnings-report release period, investors are focusing more on the delivery of results. Over the medium term, if external disruptions ease at the margin and industry catalysts continue to be realized, the STAR Market 200 (科创200) has the potential to move its center of gravity upward.

As of April 2, 2026, 15:00, among the constituent stocks of the SSE STAR Market 200 Index (000699), winners and losers have been mixed. Huiyu Pharmaceutical led the gain with an increase of 10.77%, WateR Air Products rose 7.30%, and Xinyichang rose 5.74%. Star Huan Technology was the biggest decliner. The latest quoted price of the Penghua STAR Market 200 ETF (588240) is 1.51 yuan.

The Penghua STAR Market 200 ETF tracks the SSE STAR Market 200 Index closely. The SSE STAR Market 200 Index selects 200 securities from the STAR Market on the Shanghai Stock Exchange with smaller market caps and better liquidity as its sample. The SSE STAR Market 200 Index, together with the SSE STAR Market 50 Index constituents and the SSE STAR Market 100 Index, forms the SSE STAR Market size index series, reflecting the overall performance of STAR Market listed companies’ securities across different market-cap segments.

The Penghua STAR Market 200 ETF (588240) has three strengths: a “hard technology” logic, an opportunity for “small and micro-cap (small and mid-market)”, and a “20% up-and-down board” elasticity. It is the “front-runner” in historical rebound-style market rallies. The STAR Market 200 Index brings together potential leading “dark horses,” with a balanced and diverse industry mix. Among them, the healthcare/biopharma sector accounts for nearly 15%. As of March 27, 2026, since the “9.24” rally, the STAR Market 200 Index has risen 162.69%, and since 2025 it has risen 73.99%. Both figures are well above major small and micro-cap benchmarks such as the CSI 1000, CSI 2000, and Guozheng 2000, as well as the ChiNext 200 and other mainstream small and micro-cap indices, and it also leads the Beizheng 50.

Data shows that as of March 31, 2026, the top ten weight stocks of the SSE STAR Market 200 Index (000699) are Changguang Huaxin, Tengjing Technology, Jiguang Technology, Deko Li, Jingzhida, Ukerde, Jepte, Jiayuan Technology, Juhua Materials, and Wice Technology. The combined weighting of the top ten is 16.73%.

Penghua STAR Market 200 ETF (588240), over-the-counter connection (A: 023926; C: 023927).